These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 16419068)
21. Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history. McDowell ME; Occhipinti S; Gardiner RA; Chambers SK BJU Int; 2012 Apr; 109 Suppl 3():64-70. PubMed ID: 22458497 [TBL] [Abstract][Full Text] [Related]
22. Disparities Associated with Shared Decision-making in Prostate Cancer Screening. Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068 [TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen screening among young men in the United States. Scales CD; Antonelli J; Curtis LH; Schulman KA; Moul JW Cancer; 2008 Sep; 113(6):1315-23. PubMed ID: 18696715 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen concentration in young men: new estimates and review of the literature. Sutcliffe S; Pakpahan R; Sokoll LJ; Elliott DJ; Nevin RL; Cersovsky SB; Walsh PC; Platz EA BJU Int; 2012 Dec; 110(11):1627-35. PubMed ID: 22502603 [TBL] [Abstract][Full Text] [Related]
25. Temporal and Racial Trends in Prostate-specific Antigen Screening for U.S. Men With a Family History of Prostate Cancer. Dalela D; Malchow T; Butaney M; Majdalany S; Corsi NJ; Rakic I; Sood A; Rogers C; Abdollah F Urol Pract; 2023 Sep; 10(5):484-492. PubMed ID: 37347799 [TBL] [Abstract][Full Text] [Related]
26. Trends in prostate-specific antigen test use, 2000-2005. Ross LE; Taylor YJ; Howard DL Public Health Rep; 2011; 126(2):228-39. PubMed ID: 21387953 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132 [TBL] [Abstract][Full Text] [Related]
28. Formative evaluation of the prostate cancer screening practices of African-American physicians. Stroud L; Ross LE; Rose SW J Natl Med Assoc; 2006 Oct; 98(10):1637-43. PubMed ID: 17052055 [TBL] [Abstract][Full Text] [Related]
29. Screening for prostate cancer in African Americans. Moul JW Curr Urol Rep; 2000 May; 1(1):57-64. PubMed ID: 12084342 [TBL] [Abstract][Full Text] [Related]
30. Mining laboratory data to describe prostate specific antigen testing and prostate cancer in Johannesburg, South Africa. Maphayi MR; Cassim N; Bello B; George JA Pan Afr Med J; 2020; 35():61. PubMed ID: 32537065 [TBL] [Abstract][Full Text] [Related]
31. Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes. Riviere P; Kalavacherla S; Banegas MP; Javier-Desloges J; Martinez ME; Garraway IP; Murphy JD; Rose BS Cancer; 2023 Jan; 129(1):82-88. PubMed ID: 36345568 [TBL] [Abstract][Full Text] [Related]
32. Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases. Glenn BA; Bastani R; Maxwell AE; Mojica CM; Herrmann AK; Gallardo NV; Swanson KA; Chang LC Health Psychol; 2012 Sep; 31(5):562-70. PubMed ID: 22708522 [TBL] [Abstract][Full Text] [Related]
33. Awareness and use of the prostate-specific antigen test among African-American men. Ross LE; Uhler RJ; Williams KN J Natl Med Assoc; 2005 Jul; 97(7):963-71. PubMed ID: 16080666 [TBL] [Abstract][Full Text] [Related]
34. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Zeliadt SB; Penson DF; Albertsen PC; Concato J; Etzioni RD Cancer; 2003 Aug; 98(3):496-503. PubMed ID: 12879465 [TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen as predictor of prostate cancer in black men and white men. Whittemore AS; Lele C; Friedman GD; Stamey T; Vogelman JH; Orentreich N J Natl Cancer Inst; 1995 Mar; 87(5):354-60. PubMed ID: 7531773 [TBL] [Abstract][Full Text] [Related]
36. Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Hughes L; Zhu F; Ross E; Gross L; Uzzo RG; Chen DY; Viterbo R; Rebbeck TR; Giri VN Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):53-60. PubMed ID: 22144497 [TBL] [Abstract][Full Text] [Related]
37. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. Howrey BT; Kuo YF; Lin YL; Goodwin JS J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961 [TBL] [Abstract][Full Text] [Related]
38. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Fowler JE; Bigler SA; Farabaugh PB Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526 [TBL] [Abstract][Full Text] [Related]
39. The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study. Moses KA; Zhao Z; Bi Y; Acquaye J; Holmes A; Blot WJ; Fowke JH Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):424-429. PubMed ID: 28695916 [TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Ross LE; Coates RJ; Breen N; Uhler RJ; Potosky AL; Blackman D Prev Med; 2004 Jun; 38(6):732-44. PubMed ID: 15193893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]